ArticleBMC cancer2023

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.

Chi-Shin Tseng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.